iMDx Inc.

Heading to #ASHI2025? 🌴 Visit @iMDxInc 311! 🎤 Symposium: GraftAssureIQ – Enabling In-House dd-cfDNA Testing in Transplant Research 🗓 Oct 9 | 12:40–1:35 pm ET | Grand Cypress Ballroom A–C See you there! @ASHIHQ 🔗 Info: 6363663.hs-sites.com/ashi2025 #iMDx

@iMDxInc will showcase GraftAssure™ & GraftAssureIQ™ at @IATDMCT (Singapore, 9/24) + ASHI (Orlando, 10/9). “In-house testing will bring care where it belongs – closer to the patient.” – Josh Riggs, CEO 🔗 investors.imdxinc.com/news-releases/… #TransplantInnovation #Transplant #iMDx $IMDX

iMDx to Participate in NYC Investment Conferences Sept. 8 - 11. @iMDxInc, (Nasdaq: IMDX), today announced participation in investor conferences hosted by both H.C. Wainwright and Lake Street Capital Markets. Click for more: investors.imdxinc.com/news-releases/…

It’s the last day of #WTC2025! 🎉 Huge turnout, great convos, and some fun stuffy giveaways 🐻 🎤 Don’t miss @iMDxInc's dd-cfDNA abstract presentation today—key data you won’t want to miss. #iMDx

Today’s the day! 🎉 WTC 2025 is here — stop by booth 324 to explore the future of transplant diagnostics with @iMDxInc . Don’t miss our 3 key events happening this week! #WTC2025 #ddcfDNA

New data from @iMDxInc shows 78% PPV & 93% NPV for kidney transplant rejection using our combined dd-cfDNA score. Catch our presentation (8/6 @ 10:45am). Visit Booth #324 at #WTC25! 🧬 Read here: hubs.li/Q03zFhms0 #iMDx #ddcfDNA #TransplantInnovation $IMDX

🚀🚨 Join @iMDxInc on Aug 15 for a virtual KOL event with Dr. Langone on dd‑cfDNA in transplant care + GraftAssure™ tech. Learn how in‑house testing is changing the game. Register now! Link to full post here: hubs.li/Q03zcMM50 #transplant #biotech #iMDx $IMDX

🌟 #ESOT2025 is here! 🌟 Heading to the exhibit hall? Don’t forget to stop by Booth D46 to chat with the @iMDxInc team and explore GraftAssureIQ™. 🔗 hubs.li/Q03v3nGX0 #TransplantInnovation #iMDx #GraftAssure

We’re headed to #ESOT2025! Visit @iMDxInc at Booth D46 to explore GraftAssureIQ™. 📅 June 29–July 2 | 📍 London, UK 🔗 hubs.li/Q03v3lsr0 See you there! #iMDx #TransplantInnovation

Attending ASHI's 2025 Educational Workshop? @iMDxInc is here! Catch Jim Fee on June 27 at 1:15 PM as he presents on Novel Decentralized dd-cfDNA Testing. Let’s connect in Detroit! #ASHI2025 #iMDx #ddcfDNA #TransplantInnovation

Full Press Release: investors.imdxinc.com/news-releases/…

@iMDxInc reports head-to-head data! “Data like this is highly valuable. Said Josh Riggs, CEO “[It] give us confidence that our platform performs on par with NGS-based options currently on the market”. Catch the full study data at #ESOT2025, BoothD46. Link in comments. $IMDX

@OncocyteCorp is now @iMDxInc Inc. — Insight Molecular Diagnostics Inc. 💬 This rebrand “symbolically support[s] our aim to put doctors, laboratory technicians, and researchers at the center of what we do.” – Andrea James Read here: hubs.li/Q03sp0M-0 #iMDx #OCX $OCX

📄 Don’t miss our online abstracts/presentations - asco.org/abstracts-pres… meetings.asco.org/abstracts-pres…

We’re at #ASCO25! Meet the @OncocyteCorp team & check out our latest in cancer diagnostics. Access our online abstracts/presentations via the links in the comments. Let’s shape the future of oncology together. 💡 #Immunotherapy #Innovation #OCX #WhereTomorrowLives $OCX

🚀 Big news from @Oncocyte! #Medicare has set national pricing for our transplant rejection test—an exciting step toward #FDA clearance and broader adoption. “We believe this reflects the value of our tech,” said CEO Josh Riggs. Read about it here: hubs.li/Q03ndk4X0 #OCX

In case you missed it — #EFI2025 wrapped up Saturday in beautiful Prague! We had a great week connecting with laboratory professionals and discussing GraftAssure RUO. Big congrats to our raffle winners — and thanks to everyone who stopped by Booth #9! #Transplant #OCX

We’re headed to #EFI2025 in Prague! 🇨🇿 Visit Booth #9 to chat about GraftAssure—our transplant monitoring tool—and enter our #DailyRaffle! 🎟️ #TransplantCare #OCX (@OncocyteCorp)

Big step forward! IRB approved & top U.S. transplant centers joining our trial. “We’re building strong momentum,” said CEO Josh Riggs. Exciting milestones ahead! 🧬 Click here: hubs.li/Q03kqt_v0 @OncocyteCorp #OCX #clinicalTrials #Transplant #Biotech #WhereTomorrowLIVES